These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15604884)

  • 1. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
    Zhao WL; Chen SJ; Shen Y; Xu L; Cai X; Chen GQ; Shen ZX; Chen Z; Wang ZY
    Leuk Lymphoma; 2001; 42(6):1265-73. PubMed ID: 11911407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide, a therapeutic agent for APL.
    Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
    Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
    Nitto T; Sawaki K
    J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
    Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
    Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
    Chen Z; Wang ZY; Chen SJ
    Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
    Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
    Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J
    J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
    N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
    Xu SN; Chen JP; Liu JP; Xia Y
    Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide: mechanisms of action.
    Davison K; Mann KK; Miller WH
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.